Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate efficacy and safety of 4 and 8 million units Betaferon(R)/Betaseron(R) (interferon beta-1b) given subcutaneously every other day over 24 weeks in patients with chronic viral cardiomyopathy

Next Previous
X
Search
Trial Profile

Double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate efficacy and safety of 4 and 8 million units Betaferon(R)/Betaseron(R) (interferon beta-1b) given subcutaneously every other day over 24 weeks in patients with chronic viral cardiomyopathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Adenovirus infections; Cardiomyopathies; Enterovirus infections; Parvovirus infections
  • Focus Therapeutic Use
  • Acronyms BICC
  • Sponsors Bayer HealthCare Pharmaceuticals

    • Most Recent Events

    • 11 Nov 2008 Secondary endpoint 'Exercise testing' has not been met, according to an American Heart Association media release.
    • 11 Nov 2008 Secondary endpoint 'Left ventricular ejection fraction' has not been met, according to an American Heart Association media release.
    • 11 Nov 2008 Secondary endpoint 'Quality of life' has not been met, according to an American Heart Association media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top